Cogent Biosciences Inc. (COGT)
| Bid | 6.08 |
| Market Cap | 693.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -263.71M |
| EPS (ttm) | -1.94 |
| PE Ratio (ttm) | -3.14 |
| Forward PE | -3.92 |
| Analyst | Buy |
| Ask | 6.16 |
| Volume | 83,377 |
| Avg. Volume (20D) | 1,360,577 |
| Open | 6.24 |
| Previous Close | 6.48 |
| Day's Range | 5.99 - 6.44 |
| 52-Week Range | 5.88 - 12.61 |
| Beta | 0.08 |
About COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon ...
Analyst Forecast
According to 7 analyst ratings, the average rating for COGT stock is "Buy." The 12-month stock price forecast is $14.5, which is an increase of 138.10% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST DataBezuclastinib is COGT's main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT's SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its mai...